pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ALX ONCOLOGY HOLDINGS drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
US regulatory status: approved. Molecular target: DNA.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records.
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
Development asset linked to ALX ONCOLOGY HOLDINGS in public FDA and regional records. Mechanism: Tubulin inhibitor.
Antineoplastic and immunomodulating agents (L01) compound in ALX ONCOLOGY HOLDINGS's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.
US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.